← All trials
NCT03831295
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2019
- Primary completion
- Jun 12, 2022
- Completion date
- Jun 12, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Stanford UniversityLead sponsor
- Stanford UniversityOverall official - principal investigator
- Stanford UniversitySponsor investigator
- Stanford UniversityOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.